EMEA-003246-PIP01-22
Key facts
| Active substance |
Golidocitinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0386/2022
|
| PIP number |
EMEA-003246-PIP01-22
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of peripheral T cell lymphoma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Dizal (Jiangsu) Pharmaceuticals Co., Ltd.
E-mail: info@dizalpharma.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|